Telik Inc. (TELK) Friday reported fourth-quarter net loss of $.177 million or $0.66 per share, narrower than $2.50 million or $1.38 per share reported last year.
Loss for the three-month period narrowed due to lower expenses. Research and development for the period dropped to $736 thousand from $1.10 million last year. General and administrative costs declined to $1.03 million from $1.40 million last year.
Palo Alto, California-based Telik is a clinical stage drug development company focused on discovering and developing small molecule drugs to treat cancer.
For comments and feedback: editorial@rttnews.com